Victor Shi

4 ta ish

Novartis (Switzerland)

1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

   John J.V. McMurray, Milton Packer, Akshay S. Desai +8

   Maqola20146 iqtibos

   ABIABI:AkademIndex/2026.other.295755

2. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

   George L. Bakris, Pantelis Sarafidis, Matthew R Weir +9

   Maqola20103 iqtibos

   ABIABI:AkademIndex/2026.other.535137

3. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

   Scott D. Solomon, John J.V. McMurray, Inder S. Anand +31

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295865

4. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

   Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett +22

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295867